Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Net Cash Flow (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Net Cash Flow for 13 consecutive years, with $498000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 95.94% to $498000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $20.1 million, a 16.11% increase, with the full-year FY2025 number at $20.1 million, up 16.11% from a year prior.
  • Net Cash Flow was $498000.0 for Q4 2025 at Niagen Bioscience, down from $3.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $28.0 million in Q1 2021 to a low of -$7.2 million in Q1 2022.
  • A 5-year average of $2.4 million and a median of $525000.0 in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: tumbled 500.57% in 2021, then skyrocketed 4472.08% in 2025.
  • Niagen Bioscience's Net Cash Flow stood at -$4.9 million in 2021, then soared by 247.02% to $7.2 million in 2022, then tumbled by 92.31% to $552000.0 in 2023, then skyrocketed by 2121.38% to $12.3 million in 2024, then tumbled by 95.94% to $498000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Net Cash Flow are $498000.0 (Q4 2025), $3.8 million (Q3 2025), and $4.8 million (Q2 2025).